• Plk1-Dependent Regulation of p31comet in Mitotic Checkpoint

  2026-05-22

  This study elucidates how Polo-like kinase 1 (Plk1) regulates the activity of p31comet during mitotic checkpoint complex (MCC) disassembly, revealing a phosphorylation-dependent control mechanism. The findings clarify the balance between MCC assembly and disassembly, with significant implications for understanding mitotic fidelity and potential translational approaches in cell cycle research.

• Topotecan HCl: A Potent Topoisomerase 1 Inhibitor for Oncolo

  2026-05-22

  Topotecan HCl is a validated topoisomerase 1 inhibitor with potent antitumor efficacy. Its ability to stabilize the topoisomerase I-DNA complex induces DNA damage and apoptosis in rapidly dividing tumor cells. This article details its mechanism, evidence, and protocol integration for translational cancer research.

• Lymphodepleting Chemotherapy Primes Tumor Antigenicity for T

  2026-05-21

  Sagie et al. reveal that lymphodepleting chemotherapy enhances the efficacy of neoantigen-directed T cell therapies by remodeling tumor antigen presentation. Through immunoproteasome activation and increased HLA-I expression, chemotherapy synergistically augments T cell-mediated tumor recognition, offering new avenues for improving adoptive cell therapy in solid tumors.

• Optimizing Cardiovascular Research with Nadolol (SQ-11725)

  2026-05-21

  Nadolol (SQ-11725) from APExBIO offers bench scientists a reliable, high-fidelity tool for dissecting beta-adrenergic signaling in hypertension and angina models. This guide translates recent pharmacokinetic insights into actionable workflows and troubleshooting strategies for reproducible results.

• ECL Western Blotting Substrate: Technical Protocol and Best

  2026-05-20

  ECL Western Blotting Substrate (SKU K2187) offers a sensitive, nonradioactive solution for detecting horseradish peroxidase (HRP) in chemiluminescent Western blot assays. It is optimal for protein detection in molecular biology, cancer biology, and signal transduction research, but should not be used for fluorescent or radioisotopic workflows.

• Sequencing Therapies in Waldenström Macroglobulinemia: Genom

  2026-05-20

  This review critically examines evolving approaches to treatment sequencing in Waldenström macroglobulinemia, emphasizing the integration of MYD88 and CXCR4 mutational status into regimen selection. The findings highlight the importance of genomic profiling and personalized therapy, setting a new framework for clinical decision-making in this rare lymphoma.

• GS-441524 Prodrug: Mechanistic Insights and Assay Impact

  2026-05-19

  Explore the mechanistic foundations and translational impact of GS-441524 prodrug research for antiviral development. This article offers a unique, in-depth analysis of GS-441524's conversion pathways, pharmacokinetics, and assay considerations, advancing beyond conventional workflow summaries.

• Lymphodepleting Chemotherapy Enhances T Cell Therapy via Ant

  2026-05-19

  This study demonstrates that lymphodepleting chemotherapy, including DNA synthesis inhibitors, can significantly boost the efficacy of neoantigen-directed adoptive T cell therapies by remodeling the tumor antigenic landscape. Enhanced immunoproteasome activity and HLA-I upregulation together facilitate better tumor recognition and killing by T cells, with direct implications for the optimization of immunotherapy regimens.

• Topotecan HCl: Applied Workflows for Antitumor and DNA Damag

  2026-05-18

  Topotecan HCl stands out as a topoisomerase 1 inhibitor validated for both cancer cytotoxicity and mechanistic DNA damage studies. This guide translates latest reference findings and peer-driven workflows into actionable, optimized lab protocols for tumor and neuroinflammation models.

• Phebestin as a Potent Aminopeptidase Inhibitor in Malaria Mo

  2026-05-18

  This study identifies phebestin, a bestatin-related aminopeptidase inhibitor, as a highly effective antiplasmodial agent with nanomolar potency against both chloroquine-sensitive and -resistant Plasmodium falciparum strains. These findings provide a foundation for targeting peptidase-mediated pathways in malaria therapy and highlight the value of structurally informed drug design.

• Z-WEHD-FMK: Advanced Caspase Inhibition for Inflammation Res

  2026-05-17

  Z-WEHD-FMK (Z-Trp-Glu(OMe)-His-Asp(OMe)-FMK) delivers precise, irreversible inhibition of inflammatory caspases for dissecting cell signaling in pyroptosis, apoptosis, and infectious disease models. This guide translates cutting-edge findings—including HOXC8’s regulation of pyroptosis—into actionable protocols and troubleshooting strategies, maximizing the impact of APExBIO’s caspase inhibitor in advanced research workflows.

• P2RX1 Drives Mitochondrial Apoptosis in Ph+ ALL via Ca2+/CaM

  2026-05-16

  Li et al. (2025) reveal that P2RX1 overexpression sensitizes Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) cells to mitochondrial apoptosis by disrupting calcium signaling and suppressing the PI3K/Akt pathway. These mechanistic insights highlight novel therapeutic targets and demonstrate the value of precise apoptosis detection in leukemia research.

• Fludarabine: Mechanistic Insights & Strategy for Hematologic

  2026-05-15

  This in-depth article guides translational researchers through the mechanistic rationale, experimental best practices, and strategic integration of Fludarabine—a benchmark DNA synthesis inhibitor—in leukemia and multiple myeloma research. By combining recent clinical insights with protocol recommendations and competitive context, we elucidate how Fludarabine enables next-generation mechanistic and translational workflows, with special consideration for genomic stratification in rare lymphoproliferative disorders.

• Fludarabine: DNA Synthesis Inhibitor in Myeloma and Leukemia

  2026-05-15

  Fludarabine is a gold-standard DNA synthesis inhibitor pivotal for apoptosis induction and cell cycle arrest in leukemia and multiple myeloma research. Its robust, reproducible action and APExBIO’s high-grade formulation empower advanced mechanistic studies, with optimized workflows ensuring high assay fidelity and troubleshooting flexibility.

• Selective Nanomolar IRAP Inhibitors via α-Hydroxy-β-Amino Ac

  2026-05-14

  This study introduces a highly selective, nanomolar inhibitor for insulin-regulated aminopeptidase (IRAP) based on functionalized α-hydroxy-β-amino acid derivatives of bestatin. The combination of stereoselective synthetic strategies and structural validation advances the field of targeted M1 zinc aminopeptidase inhibition, with implications for immunological and cognitive research.

15925 records 6/1062 page Previous Next First page 上5页 678910 下5页 Last page